This heat-sensitive recording material is configured to contain, as a color-developing compound, at least one compound represented by one of formulas (1)-(3): ##STR00001##

This application is directed to inhibitors of RAD51 represented by the following structural formula, ##STR00001##
and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

This application is directed to inhibitors of RAD51 represented by the following structural formula, ##STR00001##
and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

This application is directed to inhibitors of RAD51 represented by the following structural formula,

##STR00001##

and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

This application is directed to inhibitors of RAD51 represented by the following structural formula,

##STR00001##

and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

The present invention provides compounds of Formula (I)

##STR00001##

as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

The present invention provides compounds of Formula (I)

##STR00001##

as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

There are provided, inter alia, methods and compounds for activating a proliferative program in competent adult chondrocytes.

There are provided, inter alia, methods and compounds for activating a proliferative program in competent adult chondrocytes.

A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.